Epstein-barr virus infection and posttransplant lymphoproliferative disorder

American Journal of Transplantation

Volumn 13, Issue SUPPL. 3, 2013, Pages 41-54

  Green, Michael ^a   Michaels, M G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Epstein Barr virus; Malignancy; Organ transplantation; Posttransplant lymphoproliferative disorder

Indexed keywords

ANTIVIRUS AGENT; CD20 ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MONOCLONAL ANTIBODY;

ADULT; ANIMAL; CHILD; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; METABOLISM; MOUSE; POSTOPERATIVE COMPLICATION; REVIEW; TRANSPLANTATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIVIRAL AGENTS; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERFERONS; LYMPHOPROLIFERATIVE DISORDERS; MICE; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION; TREATMENT OUTCOME; VIRAL LOAD;

MLCS; MLOWN;

EID: 84878599925     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12004     Document Type: Article

References (97)

1. Allen U, Preiksaitis J. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4): S87-S96.
2. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-492.
3. Green M, Webber S. Posttransplantation lymphoproliferative disorders. Pediatric clinics of North America. 2003; 50: 1471-1491.
4. Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6: 1906-1912.
5. Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6: 1906-1912.
6. Caillard S, Lamy FX, Quelen C, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: Report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 2012; 12: 682-693.
7. Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005; 80: 193-197.
8. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719-727.
9. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection. J Infect Dis 1985; 152: 876-886.
10. Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood 2008; 111: 1420-1427.
11. Mazariegos GV. Intestinal transplantation: Current outcomes and opportunities. Curr Opin Organ Transplant 2009; 14: 515-521.
12. Caillard S, Lelong C, Pessione F, Moulin B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry. Am J Transplant 2006; 6: 2735-2742.
13. Kremers WK, Devarbhavi HC,Wiesner RH, Krom RAF,MaconWR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: Incidence, risk factors and survival. Am J Transplant 2006; 6(Pt 1): 1017-1024.
14. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222-2230.
15. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28: 1038-1046.
16. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 1: 702-703.
17. Riley KJ, Rabinowitz GS, Yario TA, Luna JM, Darnell RB, Steitz JA. EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency. EMBO J 2012; 31: 2207-2221.
18. Callan MF, Tan L, Annels N, et al. Direct visualization of antigenspecific CD8+ T-cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998; 187: 1395-1402.
19. Martinez OM. The biology of Epstein-Barr virus and posttransplant lymphoproliferative disease. In: Dharnidharka VR, Green M, Webber S, eds. Post-Transplant Lymphoproliferative Disorders. New York: Springer; 2010, pp. 29-44.
20. McKnight JL, Cen H, Riddler SA, et al. EBV gene expression, EBNA antibody responses and EBV+ peripheral blood lymphocytes in post-transplant lymphoproliferative disease. Leukemia Lymphoma 1994; 15: 9-16.
21. Smets F, Latinne D, Bazin H, et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002; 73: 1603-1610.
22. Meij P, van Esser JW, Niesters HG, et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101: 4290-4297.
23. Macedo C, Donnenberg A, Popescu I, et al. EBV-specific memory CD8+T-cell phenotype and function in stable solid organ transplant patients. Transplant Immunol 2005; 14: 109-116.
24. Falco DA, Nepomuceno RR, Krams SM, et al. Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation 2002; 74: 501-510.
25. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBVPTLD Task Force and TheMayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517-1525.
26. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723-1728.
27. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7: 2619-2625.
28. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557.
29. Grinyo J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90: 1521-1527.
30. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
31. Jonigk D, Laenger F, Maegel L, et al. Molecular and clinicopathological analysis of Epstein-Barr virus-associated posttransplant smooth muscle tumors. Am J Transplant 2012; 12: 1908-19017.
32. Swerdlow SH, International Agency for Research on Cancer., World Health Organization. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer, 2008.
33. Gross T OM, Perkins S, Park J, Lynch J, Cairo M, Smith L, Hayashi R. Low-dose chemotherapy and rituximab for post-transplant disease (PTLD): A Children's Oncology Group report. Am J Transplant 2012; 12: 3069-3175.
34. Migliazza L, Lopez Santamaria M, Murcia J, et al. Long-term survival expectancy after liver transplantation in children. J Pediatr Surg 2000; 35: 5-7; discussion, 8.
35. Kaditis AG, Phadke S, Dickman P, Webber S, Kurland G, Michaels MG. Mortality after pediatric lung transplantation: Autopsies vs. clinical impression. Pediatr Pulmonol 2004; 37: 413-418.
36. Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DL. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: Relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 1992; 166: 986-994.
37. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83: 2715-2722.
38. Preiksaitis J. Epstein-Barr viral load testing: Role in the prevention, diagnosis and management of posttransplant lymphoproliferative disorders. In: Dharnidharka VR, Green M, Webber S, eds. Post- Transplant Lymphoproliferative Disorders. New York: Springer, 2010, pp. 45-68.
39. Rowe DT,Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: Its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001; 3: 79-87.
40. Rowe DT,Qu L, Reyes J, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997; 35: 1612-1615.
41. Tsai DE, Douglas L, Andreadis C, et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: Results of a two-arm prospective trial. Am J Transplant 2008; 8: 1016-1024.
42. Wadowsky RM, Laus S, Green M,Webber SA, Rowe D. Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol 2003; 41: 5245-5249.
43. Schauer E,Webber S, Kingsley L, Green M, Rowe D. Increased Ignull B lymphocytes in the peripheral blood of pediatric solid organ transplant recipientswith elevated Epstein-Barr viral loads. Pediatr Transplant 2009; 13: 311-318.
44. Preiksaitis JK, Pang XL, Fox JD, Fenton JM, Caliendo AM, Miller GG. Interlaboratory comparison of Epstein-Barr virus viral load assays. Am J Transplant 2009; 9: 269-279.
45. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274.
46. Fryer JF HA, Wilkinson DE, Minor PD and the Collaborative Study Group. Collaborative study to evaluate the proposed 1st WHO International Standard for Epstein-Barr Virus (EBV) for nucleic acid amplification (NAT)-based assays. WHO ECBS Report 2011; WHO/BS/11.XXXX: 1-43.
47. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80Suppl): S254-S264.
48. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989; 321: 1080-1085.
49. Macedo C, Zeevi A, Bentlejewski C, et al. The impact of EBV load on T-cell immunity in pediatric thoracic transplant recipients. Transplantation 2009; 88: 123-128.
50. Lee TC, Goss JA, Rooney CM, et al. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant 2006; 20: 689-694.
51. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporinsteroid therapy. Lancet 1984; 1: 583-587.
52. Green M. Management of Epstein-Barr virus-induced posttransplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1: 103-108.
53. Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder (bigstar). Am J Transplant 2011; 11: 336-347.
54. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virusinduced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306: 913-918.
55. Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: A meta-analysis. Scand J Infect Dis 1999; 31: 543-547.
56. McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604-16011.
57. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virusassociated lymphoid malignancies. Blood 2007; 109: 2571-2578.
58. Shirley CM, Chen J, Shamay M, et al. Bortezomib induction of C/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood 2011; 117: 6297-6303.
59. Shapiro RS, Chauvenet A, McGuire W, et al. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N Engl J Med 1988; 318: 1334.
60. Ippoliti G, Martinelli L, Lorenzutti F, et al. Posttransplant lymphoproliferative disease after heart transplantation on Sandimmune therapy: Treatment with interferon alfa-2b and intravenous immunoglobulin. Transplantation Proc 1994; 26: 2660-2661.
61. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-1353.
62. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84: 972-984.
63. Swinnen LJ. Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 2000; 11(Suppl 1): 45-48.
64. Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti- CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: Long-term experience from a single center. Transplantation 2005; 80: 1692-1698.
65. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901-2906.
66. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053-3057.
67. Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: Proceed with caution. Ann Hematol 2007; 86: 599-607.
68. Webber SA HW, Faro A, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory PTLD after pediatric solid organ transplantation: Multicenter experience from a registry and from prospective clinical trial. Blood 2004; 104: 213a.
69. Milpied N, Vasseur B, Parquet N, et al. Humanized anti- CD20 monoclonal antibody (rituximab) in post transplant Blymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000; 11(Suppl 1): 113-116.
70. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005; 23: 6481-6488.
71. Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003; 9(Pt 2): 3945S-3952S.
72. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell posttransplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196-206.
73. Cavaliere R, Petroni G, Lopes MB, Schiff D. Primary central nervous system post-transplantation lymphoproliferative disorder: An International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 2010; 116: 863-870.
74. Comoli P, Basso S, Labirio M, Baldanti F, Maccario R, Locatelli F. T-cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis 2008; 40: 68-70.
75. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108: 2942-2949.
76. Fujita Y, Leen AM, Sun J, et al. Exploiting cytokine secretion to rapidly producemultivirus-specific T-cells for adoptive immunotherapy. J Immunother 2008; 31: 665-674.
77. Comoli P, Ginevri F,Maccario R, et al. Successful in vitro priming of EBV-specific CD8+ T-cells endowed with strong cytotoxic function from T-cells of EBV-seronegative children. Am J Transplant 2006; 6: 2169-2176.
78. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic Tcell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123-1131.
79. Haque T, McAulay KA, Kelly D, Crawford DH. Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: Long-term follow-up. Transplantation 2010; 90: 93-94.
80. Elliott SL, Suhrbier A, Miles JJ, et al. Phase I trial of a CD8+ Tcell peptide epitope-based vaccine for infectious mononucleosis. J Virol 2008; 82: 1448-1457.
81. Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007; 196: 1749-1753.
82. Moutschen M, Leonard P, Sokal EM, et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein- Barr virus vaccine in healthy adults. Vaccine 2007; 25: 4697-4705.
83. Rees L, Tizard EJ, Morgan AJ, et al. A phase I trial of Epstein- Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 2009; 88: 1025-1029.
84. Abedi MR, Linde A, Christensson B, Mackett M, Hammarstrom L, Smith CI. Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice. Int J Cancer 1997; 71: 624-629.
85. Nadal D, Guzman J, Frohlich S, Braun DG. Human immunoglobulin preparations suppress the occurrence of Epstein-Barr virusassociated lymphoproliferation. Exp Hematol 1997; 25: 223-231.
86. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virusspecific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
87. Bakker NA, Verschuuren EA, Erasmus ME, et al. Epstein-Barr virus-DNA load monitoring late after lung transplantation: A surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation 2007; 83: 433-438.
88. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108: 2942-2949.
89. Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 1995; 60: 547-554.
90. Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21: 547-554.
91. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5: 2894-2900.
92. Humar A, Hebert D, Davies HD, Humar A, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006; 81: 856-861.
93. Srivastava T, Zwick DL, Rothberg PG, Warady BA. Posttransplant lymphoproliferative disorder in pediatric renal transplantation. Pediatr Nephrol 1999; 13: 748-754.
94. Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 2222-2228.
95. Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients. J Pediatr Gastroenterol Nutr 2004; 38: 198-203.
96. Martin SI, Dodson B, Wheeler C, Davis J, Pesavento T, Bumgardner GL. Monitoring infection with Epstein-Barr virus among seromismatch adult renal transplant recipients. Am J Transplant 2011; 11: 1058-1063.
97. (SRTR). OPaTNOaSRoTR. SRTR 2010 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration, HealthCare Systems Bureau, Division of Transplantation. Am J Transplant 2012; 12(Suppl 1): 1-156.